# US 2023/0404923 A1 · Use of a growth factors-enriched dry powder for relieving inflammation or injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404923 A1
- Document ID: US20230404923A1
- Status: Published application
- Kind: A1
- Application number: 18/129,289
- Filed: 2023-03-31
- Published: 2023-12-21
- Earliest claimed: 2022-06-16
- Assignees: Spirit Scientific Co. LTD.; Dao Lung Steven Lin
- Applicants: Spirit Scientific Co. LTD.
- Inventors: Chin-Ho CHEN; Dao Lung Steven LIN
- Web page: https://patentgrep.com/patent/US20230404923A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a use of a growth factors-enriched dry powder for relieving inflammation or injury, wherein each gram of the growth factors-enriched dry powder comprises more than or equal to 9×104 pg of PDGF-BB.

## Claims

### Claim 1

A method of manufacturing a growth factors-enriched dry powder, comprising:
(a) taking a unit of platelet-containing solution and performing a process of purifying platelets to obtain an ultra-pure platelet solution;
(b) performing an activation procedure to allow the platelets activation in ultra-pure platelet solution and release growth factors to obtain a platelet growth factor extract solution;
(c) performing a procedure to remove a platelet-associated structure to obtain a growth factors-enriched solution; and
(d) subjecting the growth factors-enriched solution to a drying process to obtain the growth factors-enriched dry powder.

### Claim 2 (depends on 1)

The method of claim 1, wherein, the drying process is a freeze-drying process.

### Claim 3 (depends on 1)

The method of claim 1, the process of purifying platelets in step (a) further comprises a process of removing white blood cells, so that the number of white blood cells per milliliter (mL) of the ultra-pure platelet solution is less than 106 cells.

### Claim 4 (depends on 1)

The method of claim 1, the process of purifying platelets in step (a) further comprises a process of removing plasma, so that the concentration of albumin in the ultra-pure platelet solution is less than 3 g/dL; or, the process of purifying platelets comprises a procedure to remove plasma so that the concentration of globulin in the ultra-pure platelet solution is less than 2 g/dL; or, the process of purifying platelets comprises a procedure to remove plasma so that the concentration of fibrinogen in the ultra-pure platelet solution is less than 100 μg/mL.

### Claim 5 (depends on 1)

The method of claim 1, the platelet-containing solution is whole blood, and step (a) comprises:
(a1) taking a unit of platelets-containing solution;
(a2) performing a first sedimentation process, so that the platelet-containing solution is divided into a plasma layer, a buffy coat layer, and a red blood cell layer;
(a3) removing the buffy coat layer and the red blood cells layer to obtain a plasma layer solution;
(a4) performing a second sedimentation process to allow the platelets to settle and form a pellet;
(a5) removing the supernatant and mix the pellet with a solvent to obtain the ultra-pure platelet solution.

### Claim 6 (depends on 1)

The method of claim 1, wherein, the activation procedure is a freezing and then thawing procedure (i.e., a freeze-thaw procedure), an addition of Ca2+ procedure, an addition of thrombin procedure, an addition of collagen procedure, or an addition of ADP procedure, or any combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein, the activation procedure is a freezing and then thawing procedure (freeze-thaw procedure), and the freezing and then thawing procedure (freeze-thaw procedure) comprises:
(b1) placing a container containing the ultra-pure platelet solution in liquid nitrogen to freeze the ultra-pure platelet solution; and
(b2) raising the temperature of the container to thaw the frozen ultra-pure platelet solution.

### Claim 8 (depends on 1)

The method of claim 1, wherein
(1) the content of PDGF-BB per gram (g) of growth factors-enriched dry powder is 10 pg˜3×107 pg; or
(2) the content of VEGF per gram (g) of growth factors-enriched dry powder is 2×102 pg ˜3×106 pg; or
(3) the content of FGF per gram (g) of growth factors-enriched dry powder is 10 pg ˜1×104 pg; or
(4) the content of TGF-β1 per gram (g) of growth factors-enriched dry powder is 2×105 pg˜1.2×107 pg; or
(5) the content of EGF per gram (g) of growth factors-enriched dry powder is 1×102 pg˜6×105 pg.

### Claim 9 (depends on 2)

The method of claim 2, wherein, the freeze-drying procedure comprises lowering the temperature to less than or equal to −35° C. and lowering the pressure to less than or equal to 80 mTorr.

### Claim 10 (depends on 1)

The method of claim 1, wherein, the platelet-containing solution is whole blood, apheresis platelet, leukocytes-reduced platelets apheresis, or Platelet-Rich Plasma (PRP), or any combination thereof; or,
the platelet-containing solution is derived from an autologous blood sample or an allogeneic blood sample, or a combination thereof.

### Claim 11 (depends on 5)

The method of claim 5, the solvent in step (a5) is sterile saline, water for injection, 0.45% NaCl, 4.5% hypertonic saline, sterile warm spring water, or isotonic saline; or, the platelet concentration in the ultra-pure platelet solution in step (a5) is 1×109 cells/mL to 109 cells/mL.

### Claim 12 (depends on 1)

The method of claim 1, wherein, step (c) comprises:
(c1) performing a sedimentation process to allow a platelet-associated structure to settle and form a platelet-associated structure pellet;
(c2) removing the platelet-associated structure pellet to obtain the growth factors-enriched solution.

### Claim 13

A growth factors-enriched dry powder that is prepared by a preparation method, and the preparation method comprises:
(a) taking a unit of platelet-containing solution and perform a process of purifying platelets to obtain an ultra-pure platelet solution;
(b) performing an activation procedure to allow platelets activation in ultra-pure platelet solution and release growth factors to obtain a platelet growth factor extract solution;
(c) performing a platelet-associated structure removal procedure to obtain a growth factors-enriched solution; and
(d) performing the freeze-drying procedure on growth factors-enriched solution in order to obtain the growth factors-enriched dry powder, wherein the freeze-drying procedure comprises lowering the temperature to less than or equal to −30° C. and lowering the pressure to less than or equal to 100 mTorr;
wherein, the content of PDGF-BB per gram (g) of growth factors-enriched dry powder is 10 pg˜3×107 pg.

### Claim 14 (depends on 13)

The growth factors-enriched dry powder of claim 13, wherein, the activation procedure is a procedure of freezing and then thawing (freeze-thaw procedure); and the procedure of freezing and then thawing (freeze-thaw procedure) comprises:
(b1) placing a container containing the ultra-pure platelet solution in liquid nitrogen to freeze the ultra-pure platelet solution; and
(b2) raising the temperature of the container to thaw the frozen ultra-pure platelet solution.

### Claim 15 (depends on 13)

Use of the growth factors-enriched dry powder of claim 13 in the preparation of a pharmaceutical composition or health composition for administrating an effective dose to a specific site in an individual to relieve the degree of inflammation or injury of the site.

### Claim 16 (depends on 15)

The use of claim 15, wherein the lysis procedure is a procedure of freezing and then thawing (freeze-thaw procedure); and the procedure of freezing and then thawing (freeze-thaw procedure) comprises:
(b1) placing a container containing the ultra-pure platelet solution in liquid nitrogen to freeze the ultra-pure platelet solution; and
(b2) raising the temperature of the container to thaw the frozen ultra-pure platelet solution.

### Claim 17 (depends on 15)

The use of claim 15, the process of purifying platelets in step (a) further comprises a procedure for removing white blood cells so that the number of white blood cells per milliliter (mL) of the ultra-pure platelet solution is less than 106 cells.

### Claim 18 (depends on 15)

The use of claim 15, the process of purifying platelets in step (a) further comprises a procedure for removing plasma so that the concentration of albumin in the ultra-pure platelet solution is less than 3 g/dL; or, the process of purifying platelets further comprises a procedure for removing plasma so that the concentration of globulin in the ultra-pure platelet solution is less than 2 g/dL; or, the process of purifying platelets further comprises a procedure for removing plasma so that the concentration of fibrinogen in the ultra-pure platelet solution is less than 100 μg/mL.

### Claim 19 (depends on 15)

The use of claim 15, wherein
(1) the content of VEGF per gram (g) of growth factors-enriched dry powder is 2×102 pg˜3×106 pg; or
(2) the content of FGF per gram (g) of growth factors-enriched dry powder is 10 pg˜1×104 pg; or
(3) the content of TGF-β1 per gram (g) of growth factors-enriched dry powder is 2×105 pg˜1.2×107 pg; or
(4) the content of EGF per gram (g) of growth factors-enriched dry powder is 1×102 pg˜6×105 pg.

### Claim 20 (depends on 15)

The use of claim 15, wherein the growth factors-enriched dry powder is used in the manufacture of a pharmaceutical compositions or health compositions to relieve the degree of inflammation or injury of a respiratory tract, skin, muscle, tendon, bone, joint or ligament of the individual.
